Figure S6 from RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma

Larissa Anastácio da Costa Carvalho; Nataliya Tovbis Shifrin; Manali S. Phadke; Michael F. Emmons; Ximo Pechuan-Jorge; Felix Mbuga; Oscar E. Ospina; Christopher Chow; Lillian Seu; Olivia L. Rose; Aparna Madhukeshwar Hegde; Nikhil I. Khushalani; Elsa Quintana; Keiran S.M. Smalley

doi:10.1158/2326-6066.31028318

Figure S6 from RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma

2026 Open access

Read full text

Authors: Larissa Anastácio da Costa Carvalho, Nataliya Tovbis Shifrin, Manali S. Phadke, Michael F. Emmons, Ximo Pechuan-Jorge, Felix Mbuga, Oscar E. Ospina, Christopher Chow, Lillian Seu, Olivia L. Rose, Aparna Madhukeshwar Hegde, Nikhil I. Khushalani

+2 more

Elsa Quintana, Keiran S.M. Smalley

DOI: 10.1158/2326-6066.31028318

Cited by: 0

Abstract

Supplemental Figure 6: The RMC-7977 + anti-PD1 combination reprograms the tumor microenvironment to a more pro-inflammatory state. (A) Dot plot showing the distribution of sample clusters (control, Anti-PD1, RMC-7977 and RMC-7977 + Anti-PD1) and annotations of major cell types identified. (B) Dot plot showing the expression of canonical marker genes of all group clusters.

Fields of Study & Subjects

Melanoma and MAPK Pathways Cutaneous Melanoma Detection and Management Cancer Immunotherapy and Biomarkers

Publication details

Publication date: 8 January 2026